SCHEMBL2215322

SCHEMBL2215322

NCCc1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc5c4oc4ccccc45)cc4ccnn34)cc2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PCSK9 Q8NBP7 1/20 0.35
HDAC1 Q13547 1/20 0.35
MAPT P10636 4/20 0.35
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PLAU P00749 2/20 0.34
HDAC2 Q92769 1/20 0.34
THRB P10828 1/20 0.34
F2 P00734 1/20 0.34
PLG P00747 1/20 0.34
PLAT P00750 1/20 0.34
KLK1 P06870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215156 0.95 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2214178 0.95 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2214233 0.91 DNMT1 (0.42) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2216183 0.90 ALDH1A1 (0.42) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2213958 0.89 KDM4E (0.37) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2213715 0.89 SMN1; SMN2 (0.38) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2214452 0.89 ROCK2 (0.39) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2215134 0.89 LOXL2 (0.38) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2215221 0.88 MAPT (0.42) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL2215080 0.88 LMNA (0.50) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 KDM4E 3784/4885ALDH1A1 1334/4885HPGD 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.